
    
      CM-BC2, irinotecan hydrochloride drug-eluting bead, is an investigational product being
      developed for direct injection in the tumor resection margin, in patients with recurrent high
      grade glioma (HGG), in order to prevent or delay tumor progression or recurrence.

      Patients will be enrolled and receive CM-BC2 following surgical resection of the recurrent
      high grade glioma and will attend specified study visits until 6 months post surgery.
    
  